Protein expression profiling of SLE for differential diagnosis and prediction/monitoring of flares
| Reference number | |
| Coordinator | IMMUNOVIA AB |
| Funding from Vinnova | SEK 2 000 000 |
| Project duration | August 2015 - July 2017 |
| Status | Completed |
Purpose and goal
IMMray biomarker microarray could differentiate systemic lupus erythematosus (SLE) from other autoimmune diseases such as Rheumatoid Arthritis (RA), Systemic Vasculitis and Sjögren Syndrom with high accuracy.
Expected results and effects
IMMray biomarker microarray could differentiate systemic lupus erythematosus (SLE) from other autoimmune diseases such as Rheumatoid Arthritis (RA), Systemic Vasculitis and Sjögren Syndrom with an accuracy as high as 96%.
Planned approach and implementation
The study included 315 blood samples and was designed to assess the effectiveness of IMMray blood-based biomarker signatures in differentiating SLE from three main autoimmune diseases: RA, Sjögren Syndrome and Systemic Vasculitis. In the study, SLE was detected by IMMray with 95% accuracy from the RA sample cohort and 99% from the healthy controls. When differentiated from Sjögren Syndrome and Systemic Vasculitis, the accuracy rates were 84% and 99%, respectively. SLE could be also differentiated from a pool of samples of all three autoimmune diseases with an accuracy of 96%.